Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 27;40(30):4017–4025. doi: 10.1016/j.vaccine.2022.05.046

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 3 — Cross-Reactive Neutralization against the ancestral, Beta (B.1.351) Alpha (B.1.1.7), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) strains Following Homologous or Heterologous Prime-Boost Regimen. BALB/c mice (n = 8) were immunized IM on Days 0 and 21 with 3.75 µg of CoVLP.B1351 or CoVLP (both formulated with AS03 adjuvant). NAb titers were measured against SARS-CoV-2 pseudoparticles in serum samples using a cell-based PNA targeting the ancestral, B.1.351, B.1.1.7, P.1, B.1.617.2 or B.1.1.529 strains. Half of the minimum required dilution (MRD) of the method was assigned to non-responders (i.e. 12.5). GMT with 95 % CI obtained 14 days after the boost (Day 35) for the (A) ancestral, (B) B.1.351, (C) B.1.1.7, (D) P.1, (E) B.1.617.2 or (F) B.1.1.529 strains. Statistical comparisons between the CoVLP-treated groups were performed using a One-way ANOVA followed by a Tukey post hoc test (Day 35) on log₁₀-transformed NAb titers. Significant differences are indicated with p-values on the graphs.